title: [Glucocorticoid and Bone. Beneficial effect of teriparatide on fracture risk as well as bone mineral density in patients with glucocorticoid-induced osteoporosis].
abstract: Bone metablism of glucocorticoid-induced osteopororsis (GIO) is characterised by transient increase in bone resorption and persistent suppression of bone formation caused by glucocorticoid. Teriparatide is an ideal drug for GIO, because of antagonistic effect against that pathophysiological conditions. Based on new findings of treatment for GIO around the world, teriparatide was selected as one of alternative drugs of the first line agents for GIO in revised version of the guidelines on the management and treatment of GIO of the Japanese Society for Bone and Mineral Research : 2014 update.
authors.affiliation: Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Toshitsugu
authors.initials: T
authors.lastname: Sugimoto
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D050723:Fractures, Bone / Q000188:drug therapy / Q000517:prevention & control*; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D012306:Risk; D019379:Teriparatide / Q000627:therapeutic use*
chemical_list: D005938:Glucocorticoids; D019379:Teriparatide